Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002
NCT06816433
Not Yet Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design. Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/09/2025
Locations: Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky
Conditions: Post Traumatic Stress Disorder
Register for Updates
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
NCT03039192
Completed
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/25/2025
Locations: University of Louisville Department of Psychiatry, Louisville, Kentucky
Conditions: Depressive Disorder, Major
Register for Updates
Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI
NCT04600089
Recruiting
The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
10/14/2024
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm
Register for Updates
Ketamine and Epigenetic Aging
NCT05294835
Unknown
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/07/2022
Locations: Wild Health, Lexington, Kentucky
Conditions: Depression, Post Traumatic Stress Disorder
Register for Updates
Comparison of Outcomes During MRI Sedation With Midazolam-dexmedetomidine Versus Ketamine-dexmedetomidine
NCT02129426
Terminated
This study will compare 2 different sedation drugs (Ketamine and Midazolam) when they are used with another sedating medicine called Dexmedetomidine for MRI sedation. This study hopes to measure the impact each drug has on what happens during and after MRI sedation with Dexmedetomidine
Gender:
ALL
Ages:
18 years and below
Trial Updated:
07/12/2021
Locations: University of Louisville, Louisville, Kentucky
Conditions: Sedation
Register for Updates